Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Conditions

• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo collection of blood samples
• Quality-of-Life Assessment — OTHER
  Complete questionnaires
• Questionnaire Administration — OTHER
  Complete questionnaires

Study Details

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.

Key Dates

Start date

Oct 13, 2023

Status verified

May 2026

Primary completion

Feb 1, 2030

Completion

Feb 1, 2030

Study Design

Enrollment

2,000 participants (estimated)

Arms

• Arm: Observational (questionnaires, biospecimen collection)
  Participants complete questionnaires about health-related quality of life and undergo collection of blood samples at baseline and 6, 12, 18, and 24 months.

Primary Outcome Measure

Disease free survival (DFS) [ Time Frame: Time interval after primary treatment for a cancer ends that the patient survives without any signs or symptoms of thatcancer, assessed up to 2 years ]

Locations (428)

Find similar trials in Anchorage, AK

Related Studies

• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
  Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
  PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
• Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
  PHASE2 · Recruiting · New York Medical College · Valhalla, New York
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
  PHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin